Radionetics Oncology
Kristrun Thordis Stardal is currently the Director Clinical Operations at Radionetics Oncology. With a background in nursing and extensive experience in clinical operations management in various pharmaceutical companies, Kristrun has managed and mentored clinical teams, overseen global clinical trials, and ensured compliance with FDA regulations. They have also worked as a Clinical Research Consultant, Clinical Operations Manager, and Global Clinical Project Manager in the past.
This person is not in any teams
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.